CGTLive’s Weekly Rewind – July 14, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CRISPR Therapy Shows Proof-of-Concept in Preventing Antibiotic-Resistant E. Coli Infection in Patients With Cancer

The proof-of-concept trial was in healthy volunteers, and additional studies are being planned in patients with blood cancers undergoing hematopoietic stem cell transplants.

2. Sung-Yun Pai, MD, on Further Research With Lentiviral Gene Therapy for X-SCID

The senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.

3. HEMO-CAR-T IND Gets Clinical Hold for Manufacturing Issue

Hemogenyx is currently remanufacturing the therapy without the identified splicing issue.

4. Jacob Appelbaum, MD, PhD, on Investigating SC-DARIC33 and IL-15 for AML

The senior research fellow at Fred Hutch Cancer Center discussed research trends at the 2023 ASGCT meeting.

5. RNA Therapy Shows No Benefit for ALS or FTD

Wave Life Sciences is discontinuingdevelopment of WVE-004.